Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.
1997
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Effect of cisplatin upon expression of in vivo immune tumor resistance
1993
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
2010
Management of cancer pain
1999 Standout
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths
2011 Standout
The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia
2004
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient
2008
Pathological roles of MAPK signaling pathways in human diseases
2010 Standout
Ovarian cancer
2014 Standout
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey
2004
Randomized Trial of High-Dose Chemotherapy and Blood Cell Autografts for High-Risk Primary Breast Carcinoma
2000
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
2009 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Rhabdomyolysis and Acute Kidney Injury
2009 Standout
Prospective evaluation of antiemetic outcome following high-dose chemotherapy with hematopoietic stem cell support
2001
Amputation for soft-tissue sarcoma
2003
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation
2000 Standout
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
2003
Screening for Lung Cancer*
2003
Soft-Tissue Sarcomas in Adults
2005 Standout
High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer.
1998
Low-dose dopamine: a systematic review
2002
Activation of Caspase Pathways during Iron Chelator-mediated Apoptosis
2002
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration
2005
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
2011
Use of dopamine in acute renal failure: A meta-analysis
2001
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Risk factors for brain relapse in patients with metastatic breast cancer
2004
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
2006 Standout
The prevalence of episodic pain in cancer: a survey of hospice patients on admission
2001
Targeting multidrug resistance in cancer
2006 Standout
Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach
2001
Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer
2010
Cardiorenal Syndrome
2008 Standout
The pathobiology of mucositis
2004 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Photodynamic therapy and anti-tumour immunity
2006 Standout
Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy
2016
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation
2010 Standout
Prophylaxis of Radiation-Induced Nausea and Vomiting Using 5-Hydroxytryptamine-3 Serotonin Receptor Antagonists: A Systematic Review of Randomized Trials
2010
Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
2008
Breakthrough pain: characteristics and impact in patients with cancer pain
1999
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
A review of airborne polycyclic aromatic hydrocarbons (PAHs) and their human health effects
2013 Standout
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Simultaneous Absolute Quantification of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection
2010
Selective Blockade of the Capsaicin Receptor TRPV1 Attenuates Bone Cancer Pain
2005 StandoutNobel
Prevalence of pain in patients with cancer: a systematic review of the past 40 years
2007 Standout
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
1999 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment
2003
Acute decompensated heart failure and the cardiorenal syndrome
2008
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents
2008
Preservation of Fertility in Patients with Cancer
2009 Standout
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Anemia of Chronic Disease
2005 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway
2017 StandoutNobel
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
2013 Standout
Cytochrome P450 2C8 Pharmacogenetics: A Review of Clinical Studies
2009
Prevention of High-Dose Chemotherapy–Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
2006 Standout
Meta-Analysis: Low-Dose Dopamine Increases Urine Output but Does Not Prevent Renal Dysfunction or Death
2005
Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies
2012
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
2004 Standout
Systematic review: The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence
1997
Renal Protective Agents: A Review
1999
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
The role of radiotherapy in cancer treatment
2005 Standout
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
1996
Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants
2003
Cyclosporin A Is a Broad-Spectrum Multidrug Resistance Modulator
2005
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-Dose Chemotherapy
2000 Standout
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer.
2003
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of James Raschko being referenced
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study
1999
Predictors of long-term outcome following high-dose chemotherapy in high-risk primary breast cancer
2002
Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
1996
Modulation of 5-Fluorouracil with High-Dose Leucovorin Calcium: Activity in Ovarian Cancer and Correlation with CA-125 Levels
1995
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
1995
5-Fluorouracil and High-Dose Calcium Leucovorin for Hepatocellular Carcinoma: A Phase II Trial
1995
Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation
2000
High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
1997
Phase I Trial of Interleukin-2 plus Gamma-Interferon
1992
Phase I Trial of Interleukin-2 plus Doxorubicin
1993
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
2004
Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer
2001
Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis
2000
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer
1994
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
2001
NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.
1996
Pulmonary fibrosis after bone marrow transplantation responsive to treatment with prednisone and cyclosporine.
1989
Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.
1992
Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer
1997
High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
1997
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
2001